DNase1 activity in systemic lupus erythematosus patients with and without nephropathy
Tóm tắt
The objective of the study is to determine whether the activity of DNase1 is associated to the presence of nephropathy in patients with SLE. Forty-five patients affected with SLE and renal involvement were analyzed. The type of renal involvement was type III or IV glomerulonephritis. At least two serum samples were withdrawn from each patient, one obtained in a renal flare and the other obtained in a period of clinical stability. C3 and C4 complement levels and anti-DNA antibodies were determined. DNase1 activity was measured using a radial enzyme-diffusion method. Results suggest that when comparison of DNase1 activity was established between samples obtained during a phase of active renal involvement and those obtained in the clinically stable phase, we did not find statistically significant differences. When the comparison was performed with matched samples of the same patient, DNase1 activity was lower when patients had active renal involvement than when samples were taken in clinically stable phase (21.21 μg/ml ± 16.47 vs. 25.62 μg/ml ± 18.81, p < 0.05). No difference in DNase1 activity was observed between samples positive or negative for anti-DNA antibodies. No difference in DNase1 activity was found in patients with normal or decreased levels of C3 (25.09 μg/ml ± 17.78 vs. 20.01 μg/ml ± 16.15, p = 0.073) or C4 (23.52 μm/ml ± 16.60 vs. 19.62 μg/ml ± 17.54, p = 0.060). We conclude that low DNase1 activity is associated to the active phase of type III or IV nephropathy. Therefore, it is possible that this enzyme plays an important role in the development of SLE nephropathy.
Tài liệu tham khảo
Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34:501–537
Bruneau C, Benveniste J (1979) Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. J Clin Invest 64:191–198
Brinkman K, Termaat R, Berden JH, Smeenk RJ (1990) Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol Today 11:232–234
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Aydintug AO, Jedryka-Goral A, de Ramon E, Fernandez-Nebro A, Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ruiz-Irastorza G, Ingelmo M, Hughes GR (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175
Yang LY, Chen WP, Lin CY (1994) Lupus nephritis in children—a review of 167 patients. Pediatrics 94:335–340
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:113–124
Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC (2007) Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 16:28–34
Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, Limburg P, Gmelig-Meyling F, Kater L, Kallenberg C (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595–1599
ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33:634–643
Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76:227–324
Graham KL, Utz PJ (2005) Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 17:513–517
Walport MJ (2000) Lupus, DNase and defective disposal of cellular debris. Nat Genet 25:135–136
Koutouzov S, Jeronimo AL, Campos H, Amoura Z (2004) Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 30:529–558
Laskowski M (1971) Deoxyribonuclease I. In: Boyer PD (ed) The enzymes, 3rd edn, vol 4. New York Academic Press, NY, pp 289–311
Lacks SA (1981) Deoxyribonuclease I in mammalian tissues. Specificity of inhibition by actin. J Biol Chem 256:2644–2648
Mannherz HG, Peitsch MC, Zanotti S, Paddenberg R, Polzar B (1995) A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 198:161–174
Napirei M, Wulf S, Mannherz HG (2004) Chromatin breakdown during necrosis by serum DNase1 and the plasminogen system. Arthritis Rheum 50:1873–1883
Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M (2009) DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 18:418–423
Chitrabamrung S, Bannett JS, Rubin RL, Tan EM (1981) A radial diffusion assay for plasma and serum deoxyribonuclease I. Rheumatol Int 1:49–53
Chitrabamrung S, Rubin RL, Tan EM (1981) Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1:55–60
Macanovic M, Lachmann PJ (1997) Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 108:220–226
Tan EM, Schur PH, Carr RI, Kunkel HG (1966) Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45:1732–1740
Schur PH, Sandson J (1968) Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278:533–538
Miniter MF, Stollar BD, Agnello V (1979) Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus. Arthritis Rheum 22:959–968
Berden JH (1997) Lupus nephritis. Kidney Int 52:538–558
Bell DA, Morrison B, VandenBygaart P (1990) Immunogenic DNA-related factors. Nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J Clin Invest 85:1487–1496
Dieker JW, van der Vlag J, Berden JH (2002) Triggers for anti-chromatin autoantibody production in SLE. Lupus 11:856–864
Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH (2004) Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 22:139–145
Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR, Herrmann M (2006) Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 305:161–176
Denny MF, Chandaroy P, Killen PD, Caricchio R, Lewis EE, Richardson BC, Lee KD, Gavalchin J, Kaplan MJ (2006) Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol 176:2095–2104
White S, Rosen A (2003) Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol 15:557–562
Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2:965–975
Peitsch MC, Irmler M, French LE, Tschopp J (1995) Genomic organisation and expression of mouse deoxyribonuclease I. Biochem Biophys Res Commun 207:62–68
Gaipl US, Beyer TD, Heyder P, Kuenkele S, Bottcher A, Voll RE, Kalden JR, Herrmann M (2004) Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum 50:640–649
Suzuki N, Harada T, Mizushima Y, Sakane T (1993) Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus. J Immunol 151:1128–1136
Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA (1998) Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161:4467–4471
Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89